0.3207  -0.167 (-34.28%)		02-12 16:00
Open: 0.4081 High: 0.409 Volume: 1,609,868		Pre. Close: 0.488 Low: 0.301 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.45	1-year :	0.53
Resists	First :	0.38	Second :	0.45
Pivot price	0.27
Supports	First :	0.24	Second :	0.15
MAs	MA(5) :	0.34	MA(20) :	0.26
	MA(100) :	0.51	MA(250) :	0.92
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	90	D(3) :	89.6
RSI	RSI(14): 63
52-week	High :	1.63	Low :	0.15

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NVIV ] has closed below upper band by 10.9%. Bollinger Bands are 5.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.39 - 0.39	0.39 - 0.39
Low:	0.37 - 0.37	0.37 - 0.37
Close:	0.37 - 0.37	0.37 - 0.37

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Wed, 07 Feb 2024
Invivo Therapeutics Holdings Faces Nasdaq Delisting - TipRanks

Tue, 06 Feb 2024
Bob Langer-founded device-maker declares bankruptcy - The Business Journals

Thu, 09 Mar 2023
InVivo : INSPIRE 2.0 Study In Acute Spinal Cord Injury Fails To Meet Primary Endpoint - Nasdaq

Thu, 09 Mar 2023
Why InVivo Therapeutics Shares Are Plunging Today - Yahoo Finance

Thu, 09 Mar 2023
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury - Business Wire

Wed, 13 Jul 2022
InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	3 (M)
Shares Float	3 (M)
Held by Insiders	0 (%)
Held by Institutions	3.4 (%)
Shares Short	18 (K)
Shares Short P.Month	0 (K)

EPS	-3.28
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.86
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-53.8 %
Return on Equity (ttm)	-98.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.16
Qtrly Earnings Growth	0 %
Operating Cash Flow	-10 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-0.12
PEG Ratio	0
Price to Book value	0.12
Price to Sales	0
Price to Cash Flow	-0.12

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.